Affiliate disclosure: Some links in this article are affiliate links. We may earn a commission at no additional cost to you.

Medical disclaimer: This article reviews research on chronic inflammation and aging biology. It is not medical advice, diagnosis, or treatment. Not medical advice. Consult a qualified healthcare professional before changing your diet, supplement regimen, or medical treatment plan.

The term “inflammaging” was introduced by Claudio Franceschi and colleagues in a 2000 paper in Annals of the New York Academy of Sciences as shorthand for a specific observation: that aging across multiple mammalian species is associated with chronically elevated pro-inflammatory signaling. Not acute inflammation responding to an injury or pathogen, but low-grade, persistent systemic activation of inflammatory pathways — measurable in circulating IL-6, TNF-alpha, C-reactive protein (CRP), and IL-1β even in the apparent absence of active infection or tissue damage.

In the two and a half decades since Franceschi’s framing, this has become one of the more productive organizing hypotheses in geroscience, because it offers a mechanistic bridge between aging biology and the cluster of conditions — cardiovascular disease, neurodegeneration, metabolic syndrome, sarcopenia — that tend to appear together in older adults. Whether chronic inflammation is a cause of accelerated aging, a consequence of it, or both simultaneously is still being worked out. But the correlation is consistent enough across cohort data that researchers treat it as a serious signal.

Japan is a relevant testing ground for inflammaging hypotheses for a reason that is structurally important: it has the highest documented centenarian density of any large country (approximately 92,000 centenarians per Japan Statistics Bureau data, 2023), and the longest-running systematic centenarian research program in the Okinawa Centenarian Study (OCS), which began in 1975. Studies examining whether Japanese centenarians show the expected inflammaging pattern — and in what ways they deviate from it — belong to the more informative data in this field.

Centenarian inflammatory profiles: what the OCS actually documented

Multiple publication cycles from the Okinawa Centenarian Study have included inflammatory marker measurements in the centenarian cohort. The consistent finding across OCS analyses: Okinawan centenarians show lower IL-6 levels relative to age-matched comparison groups drawn from populations not selected for exceptional longevity. One cluster of OCS analyses, led by Bradley Willcox, D. Craig Willcox, and Makoto Suzuki and their collaborators, found that centenarians with the most favorable inflammatory marker profiles also tended to maintain higher functional status scores at examination — lower CRP, lower homocysteine, and higher HDL cholesterol were associated with better performance on the functional assessments the study tracked.

Three interpretive caveats apply directly to these findings:

Survivor selection is the first and hardest one. The OCS, by design, studies people who already reached centenarian age. Whatever combination of genetics, diet, activity, and chance produced that outcome filtered out the participants before enrollment. People who aged with high inflammatory marker profiles presumably died earlier and are absent from the dataset. The lower inflammaging observed in centenarians may be partly a cause of their exceptional survival, partly a genetic correlate, and partly an artifact of having studied only the people who made it.

The pre-war cohort specificity problem. The dietary patterns documented in OCS centenarians — predominantly sweet potato, minimal processed food, oily fish, fermented soy — describe what these people ate during the first few decades of their lives. Post-WWII Okinawa has seen substantial dietary westernization, and male life expectancy in Okinawa has declined from top-3 nationally in the 1980s to approximately mid-ranking in the most recent MHLW prefectural tables. The cohort being studied does not represent current Okinawan diet.

Cohort data cannot establish individual prescriptions. The OCS finding that centenarians have lower IL-6 does not tell us which midlife dietary interventions will reduce IL-6 in a non-Japanese adult eating a different baseline diet. That requires a different study design.

JPHC cohort data: fish consumption and inflammatory markers

The Japan Public Health Center-based Prospective Cohort Study (JPHC) enrolled roughly 140,000 adults across nine prefectures from 1990 onward. It has produced dietary pattern analyses against a range of health outcomes, including inflammatory marker levels measured in subsamples.

Fish consumption frequency — relevant because EPA and DHA from marine sources modulate eicosanoid and cytokine signaling pathways that intersect with IL-6 and CRP — is associated with lower CRP in JPHC subgroup analyses, particularly in adults over 50. The association appears to strengthen with more frequent consumption, with daily consumers showing lower marker levels than weekly consumers in the analyzed subsamples.

The confounding load is substantial, and this matters for how JPHC data should be read. Japanese adults who eat oily fish daily also differ systematically from those who do not on physical activity levels, overall dietary pattern, socioeconomic factors, and a range of lifestyle variables that track with both fish consumption and inflammatory marker levels. JPHC analyses include regression adjustments for major confounders, but residual confounding in observational data of this kind is not eliminable by statistical means. The association is consistent and biologically plausible; causation is not established by the design.

Fermented soy, gut microbiome, and the inflammaging pathway

Gut-inflammation connections have become central to inflammaging research since roughly 2015, when a series of publications established that microbial dysbiosis — shifts in gut bacterial community structure — is correlated with elevated systemic inflammatory markers in older adults. The proposed mechanism involves intestinal barrier function: in aging populations, increased intestinal permeability is associated with translocation of microbial components (lipopolysaccharides in particular) into systemic circulation, activating chronic innate immune responses.

Japanese dietary patterns, particularly consistent consumption of fermented soy products — miso, natto, and their relatives — are associated with greater abundance of Bifidobacterium and Lactobacillus species in gut microbiome analyses compared to Western dietary patterns. These genera are consistently among those associated with better intestinal barrier function markers in cohort and clinical data. Whether that association translates to meaningful differences in systemic inflammatory markers specifically is harder to isolate.

A cluster of Japanese dietary cohort analyses examining fermented food intake against IL-6 and related inflammatory markers has found directional associations consistent with this pathway — higher total fermented soy intake linked to lower inflammatory marker concentrations in measured subsamples. The cohort sizes in fermented food subanalyses are generally smaller than the flagship JPHC outcomes work, and confounding from simultaneous dietary variables remains the same limitation. The finding is consistent with biological plausibility and with several smaller dietary intervention studies; it is not established as causal evidence at the level a randomized trial would provide.

What omega-3 supplementation research actually adds

Fish consumption data from JPHC and other Japanese cohorts captures a real dietary pattern in a specific population context. The supplement-form question — whether EPA/DHA capsules replicate the inflammatory marker associations observed in high-fish dietary patterns — is a distinct question with a more mixed evidence base.

Meta-analyses pooling EPA/DHA supplementation trials have consistently found modest reductions in CRP and IL-6 in populations with elevated baseline inflammatory markers. Effect sizes sit in the range of 0.1–0.4 mg/L for CRP and smaller absolute changes for IL-6 across most meta-analyses; results are heterogeneous across trials and populations. In populations with already-low baseline inflammatory markers — the kind more typical of healthy adults seeking supplementation advice — the reductions documented are smaller still, and in some trials not distinguishable from placebo.

This matters for how JPHC fish data gets translated into supplement recommendations. The JPHC cohort finding of lower CRP in high-fish consumers is not evidence that consuming fish oil capsules produces the same result in a non-Japanese adult eating a Western dietary baseline. The entire dietary context differs, not just the omega-3 intake. The extrapolation is made frequently in supplement marketing; the primary literature does not support it as cleanly as marketing typically implies.

For adults interested in EPA/DHA supplementation in the context of inflammatory marker monitoring: the evidence is strongest for individuals with documented elevated CRP or other inflammatory markers at baseline, and for doses in the 1–3 g combined EPA+DHA per day range. The supplement-form evidence in healthy adults without baseline elevation is substantially weaker. Amazon carries Nordic Naturals and comparable brands with current certificates of analysis; dose and purity documentation matter more to efficacy than brand differentiation.

Green tea polyphenols and the NF-κB pathway

Epigallocatechin-3-gallate (EGCG), the predominant polyphenol in Japanese green tea, inhibits NF-κB — a transcription factor driving IL-6, TNF-alpha, and related pro-inflammatory gene expression — in cell culture and animal experimental systems. The preclinical mechanistic rationale is well-established. The human evidence is more limited.

JPHC cohort data includes analyses of green tea consumption frequency against CRP levels. The directional finding in the largest published JPHC green tea subanalysis: daily consumption at five or more cups per day is associated with lower CRP compared to less-than-one cup per day, with the association surviving adjustment for age, sex, smoking, and BMI. The effect size is modest — the CRP difference across consumption categories is not clinically large. A separate series of Tohoku University analyses found similar directional associations, with the same limitation: the heaviest tea consumers in these cohorts also more closely follow traditional Japanese dietary patterns across the board. Isolating the tea contribution from the broader dietary context is not achievable in observational data.

No large randomized trial has established that EGCG supplementation — at doses equivalent to heavy Japanese green tea consumption — reduces CRP or IL-6 at scale in a general adult population. Small trials exist; results are directional but inconsistent across populations and doses. This remains a hypothesis with biological plausibility and supporting observational association, not established clinical evidence. For the broader mortality cohort evidence on green tea specifically, green tea and mortality in Japanese cohorts covers the JPHC and Ohsaki study data in more depth.

What the evidence supports, and where it stops

Across the threads reviewed here — centenarian inflammatory profiles from the OCS, JPHC dietary pattern data, gut microbiome fermented soy associations, omega-3 supplementation trials, and EGCG cohort findings — a coherent directional picture is visible. Its interpretive limits deserve equal weight:

Consistent across multiple lines of evidence: Japanese dietary patterns characterized by high oily fish intake, fermented soy products, and frequent green tea consumption are associated with lower inflammatory marker profiles in multiple large cohort datasets. The associations are consistent enough that biological plausibility does not require special pleading, and the candidate mechanisms are reasonably well-characterized at the cellular level.

Not established: That any of these associations reflects causation. That dietary interventions will reduce inflammatory markers in any specific individual. That reducing inflammatory markers in midlife will extend individual lifespan. That supplement-form approximations of these dietary patterns — fish oil capsules, EGCG extract, fermented soy powders — produce the same associations as the observed whole-diet patterns. The centenarian cohort findings describe survivors of a specific historical dietary context, not a generalizable prescription forward.

On the inflammaging concept itself: It remains the most productive organizing hypothesis for why aging-associated conditions cluster the way they do in late life. Whether pharmaceutical or dietary modification of chronic inflammatory signaling in humans will demonstrably modify aging trajectories at the population level is the key unanswered empirical question. The human evidence base is substantive — and not yet sufficient to support strong individual recommendations.

For dietary context, the washoku-pattern cooking literature organized around the ingredient categories that track lowest in inflammatory marker cohort analyses offers one practical angle: Amazon carries several titles by Japanese culinary authors organized around traditional meal structure. For the gut microbiome pathway and fermented food evidence in more detail, Japanese fermented foods, gut health, and cognitive longevity covers the cohort data. For the NMN and NAD+ aging trial context — where inflammaging and mitochondrial decline interact mechanistically — Japan anti-aging clinical trials: NMN and NAD+ reviews the Keio program findings.

---

Part of the Choju Lab research series. See also: Japan Blue Zones research 2026 | Green tea mortality cohort evidence